SGLT-2 Therapy Center

New SGLT1/SGLT2 inhibitor lowers HbA1c and has less hypoglycemia episodes among people who have type 1 diabetes.

Adding an SGLT2 inhibitor helps lower HbA1c and decrease variability in glucose ranges among people with type 1 diabetes.

Multiple studies find drug to be first diabetes medication to show significant reduction of liver fat.

Which is not a side effect of SGLT-2 Inhibitors?

A. Kidney failure
B. Hyperkalemia
C. Ketoacidosis
D. Hypertension
E. Increased cholesterol levels
F. Serious urinary tract infections
G. Increased bladder cancer risk
H. Serious allergic reactions

Follow the link for the answer.

FDA issues new warning regarding SGLT2 inhibitors after 12 cases of rare necrotizing fasciitis emerge.

What is a SGLT2 Inhibitor? Sodium-glucose co-transporter 2 (SGLT2) inhibitors, also called gliflozin drugs,  are a new class of diabetic medications indicated for the treatment of type 2 diabetes. They have also been found to show cardiac benefits in patients with diabetes, and are being studied for possible use in type 1 diabetes. They work by reducing the absorption of glucose via the kidneys so that excess glucose is excreted through urination.

Research still limited in regard to SGLT2 inhibitor use and its ability to reduce CVD risk in patients after revascularization

Pancreatic hormones, glucagon and insulin said partially responsible for unintended increase in glucose.

After reviewing evidence, a tool to evaluate benefit and risk has been developed for the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors.

An SGLT-2 inhibitor reduces liver fat and ALT levels in people who have type 2 diabetes.